Daren Parsa, MD
Psychiatry · Raceland, LANPI 1700947991
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.7% of the total across 412 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 20 manufacturers, the largest accounting for just 20.0% — the pattern of someone who eats at a lot of different presentations. Among psychiatry clinicians in LA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 412 payments — averaging $15.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Alkermes, Inc.$815
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$689
- Teva Pharmaceuticals USA, Inc.$600
- Otsuka America Pharmaceutical, Inc.$522
- Lundbeck LLC$456
- plus $2K from 14 others
What the payments were for
- Food & beverage$6,49099%
- Education$861%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 87 | $1,315 |
| Alkermes, Inc. | 50 | $815 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 53 | $689 |
| Teva Pharmaceuticals USA, Inc. | 32 | $600 |
| Otsuka America Pharmaceutical, Inc. | 33 | $522 |
| Lundbeck LLC | 37 | $456 |
| Johnson & Johnson | 20 | $425 |
| Vanda Pharmaceuticals Inc. | 16 | $391 |
| Neurocrine Biosciences, Inc. | 18 | $355 |
| Indivior Inc. | 15 | $266 |
| Sunovion Pharmaceuticals Inc. | 15 | $180 |
| Takeda Pharmaceuticals U.S.A., Inc. | 9 | $162 |
| Corium, LLC | 12 | $146 |
| Axsome Therapeutics, Inc. | 5 | $90 |
| E.r. Squibb & Sons, L.L.C. | 4 | $75 |
| Eisai Inc. | 2 | $29 |
| Supernus Pharmaceuticals, Inc. | 1 | $19 |
| Idorsia Pharmaceuticals US Inc | 1 | $16 |
| Hikma Pharmaceuticals USA | 1 | $14 |
| Noven Therapeutics, LLC | 1 | $11 |
How this compares
$6,575 in reported general payments places this provider in the 90th percentile of 474 psychiatry providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 67 | $220,098 |
| IngrezzaValbenazine Tosylate | 24 | $186,863 |
| AustedoDeutetrabenazine | 13 | $77,800 |
| Abilify MaintenaAripiprazole | 31 | $75,960 |
| VraylarCariprazine Hcl | 37 | $56,497 |
| PerserisRisperidone | 17 | $47,447 |
| AristadaAripiprazole Lauroxil | 16 | $47,088 |
| RexultiBrexpiprazole | 31 | $45,177 |
| TrintellixVortioxetine Hydrobromide | 64 | $32,921 |
| UzedyRisperidone | 12 | $15,460 |
| BelsomraSuvorexant | 15 | $6,417 |
| ZoloftSertraline Hcl | 12 | $5,364 |
| Quetiapine Fumarate | 332 | $5,136 |
| Hydroxyzine Pamoate | 239 | $4,318 |
| Lurasidone Hcl | 51 | $3,946 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Sustenna | $425 | $220,09867 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $355 | $186,86324 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Maintena, Rexulti | $522 | $121,13762 claims |
| Teva Pharmaceuticals USA, Inc.Austedo, Uzedy | $600 | $93,26025 claims |
| AbbVieVraylar | $1,315 | $56,49737 claims |
| Indivior Inc.Perseris | $266 | $47,44717 claims |
| Alkermes, Inc.Aristada | $815 | $47,08816 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $162 | $32,92164 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 474 psychiatry providers in Louisiana.
Other psychiatry in Raceland
- Patrick HayesLake Charles$837K
- Maria CruseThibodaux$522K
- Larry WarnerBaton Rouge$495K
- Gregory BrownShreveport$495K
- Arwen PodestaNew Orleans$466K
- Jasjit SinghShreveport$420K
- Roger BrownMandeville$216K
- Abdul KhanBaton Rouge$156K
- William ColombMandeville$117K
- Andrew MorsonNew Orleans$56K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.